medigraphic.com

2026, Number 3

<< Back Next >>

Med Crit 2026; 40 (3)

Glycemic variability in the Intensive Care Unit. Topic review and clinical case presentation

Velázquez CA, Morales RJD, Díaz GA, Alonso MD, Cruz LJ, Hidalgo LR

Language: Spanish
References: 33
Page: 227-232
PDF size: 605.01 Kb.


ABSTRACT

Introduction: glycemic variability refers to any metric that is characterized by the variation in serum glucose levels from time series monitoring over a specific period or interval. It is one of the measurements available to patients prone to developing alterations in glucose metabolism due to their critical conditions, and a tool in development for routine use within intensive care units. Objective: to describe the importance of glycemic variability as a practical tool applicable to the monitoring of patients in intensive care units, as well as a tool that provides the facility to modify the therapy used. To present the clinical condition of a patient in critical condition with traumatic burn injuries extending to 90% of the body surface. Conclusions: the use of serum glucose measurements involving changes in minimum and maximum values and over a time interval generates a useful tool to modify treatment and prevent complications that cause greater organic damage, thus modifying mortality and complications associated with the conditions of any critically ill patient. That is why glycemic variability aims to be a routine tool in intensive care units that will facilitate patient monitoring and explain the condition of metabolic imbalance susceptible to treatment.


REFERENCES

  1. Plummer MP, Bellomo R, Cousins CE, Annink CE, SundararajanK, Reddi BA, et al. Dysglycaemia in the critically ill and theinteraction of chronic and acute glycaemia with mortality.Intensive Care Med. 2014;40(7):973-980. doi: 10.1007/s00134-014-3287-7.

  2. Krinsley JS. Glycemic control, diabetic status, and mortality ina heterogeneous population of critically ill patients before andduring the era of intensive glycemic management: six andone-half years experience at a university-affiliated communityhospital. Semin Thorac Cardiovasc Surg. 2006;18(4):317-325.

  3. van den Berghe G, Wouters P, Weekers F, Verwaest C,Bruyninckx F, Schetz M, et al. Intensive insulin therapy incritically ill patients. N Engl J Med. 2001;345(19):1359-1367. doi:10.1056/NEJMoa011300.

  4. NICE-SUGAR Study Investigators; Finfer S, ChittockDR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensiveversus conventional glucose control in critically ill patients.N Engl J Med. 2009;360(13):1283-1297. doi: 10.1056/NEJMoa0810625.

  5. Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, CookDJ, Malhotra A, et al. Intensive insulin therapy and mortalityamong critically ill patients: a meta-analysis including NICESUGARstudy data. CMAJ. 2009;180(8):821-827. doi: 10.1503/cmaj.090206.

  6. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, FerrerR, et al. Surviving sepsis campaign: international guidelines formanagement of sepsis and septic shock: 2016. Intensive CareMed. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.

  7. Wu Z, Liu J, Zhang D, Kang K, Zuo X, Xu Q, et al. Expertconsensus on the glycemic management of critically illpatients. J Intensive Med. 2022;2(3):131-145. doi: 10.1016/j.jointm.2022.06.001.

  8. Krinsley JS, Schultz MJ, Spronk PE, Harmsen RE, van BraamHouckgeest F, van der Sluijs JP, et al. Mild hypoglycemia isindependently associated with increased mortality in the criticallyill. Crit Care. 2011;15(4):R173. doi: 10.1186/cc10322.

  9. NICE-SUGAR Study Investigators; Finfer S, Liu B, Chittock DR,Norton R, Myburgh JA, et al. Hypoglycemia and risk of death incritically ill patients. N Engl J Med. 2012;367(12):1108-1118. doi: 10.1056/NEJMoa1204942.

  10. Harp JB, Yancopoulos GD, Gromada J. Glucagon orchestratesstress-induced hyperglycaemia. Diabetes Obes Metab.2016;18(7):648-653. doi: 10.1111/dom.12668.

  11. Viana MV, Moraes RB, Fabbrin AR, Santos MF, GerchmanF. Assessment and treatment of hyperglycemia in criticallyill patients. Rev Bras Ter Intensiva. 2014;26(1):71-76. doi:10.5935/0103-507x.20140011.

  12. Mifsud S, Schembri EL, Gruppetta M. Stress-inducedhyperglycaemia. Br J Hosp Med (Lond). 2018;79(11):634-639.

  13. Zhang ZY, Miao LF, Qian LL, Wang N, Qi MM, Zhang YM, etal. Molecular mechanisms of glucose fluctuations on diabetic complications. Front Endocrinol (Lausanne). 2019;10:640. doi:10.3389/fendo.2019.00640.

  14. McDonnell ME, Umpierrez GE. Insulin therapy for themanagement of hyperglycemia in hospitalized patients.Endocrinol Metab Clin North Am. 2012;41(1):175-201. doi:10.1016/j.ecl.2012.01.001.

  15. Wold LE, Ceylan-Isik AF, Ren J. Oxidative stress andstress signaling: menace of diabetic cardiomyopathy. ActaPharmacol Sin. 2005;26(8):908-917. doi: 10.1111/j.1745-7254.2005.00146.x.

  16. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, etal. Activation of oxidative stress by acute glucose fluctuationscompared with sustained chronic hyperglycemia in patients withtype 2 diabetes. JAMA. 2006;295(14):1681-1687. doi: 10.1001/jama.295.14.1681.

  17. Kohnert KD, Freyse EJ, Salzsieder E. Glycaemic variability andpancreatic β-cell dysfunction. Curr Diabetes Rev. 2012;8(5):345-354. doi: 10.2174/157339912802083513.

  18. Li K, Song WJ, Wu X, Gu DY, Zang P, Gu P, et al. Associations ofserum glucagon levels with glycemic variability in type 1 diabeteswith different disease durations. Endocrine. 2018;61(3):473-481.doi: 10.1007/s12020-018-1641-1.

  19. Tomita T. Apoptosis in pancreatic β-islet cells in type 2 diabetes.Bosn J Basic Med Sci. 2016;16(3):162-179. doi: 10.17305/bjbms.2016.919.

  20. Saito S, Teshima Y, Fukui A, Kondo H, Nishio S, Nakagawa M, etal. Glucose fluctuations increase the incidence of atrial fibrillationin diabetic rats. Cardiovasc Res. 2014;104(1):5-14. doi: 10.1093/cvr/cvu176.

  21. Sun J, Xu Y, Sun S, Sun Y, Wang X. Intermittent high glucoseenhances cell proliferation and VEGF expression in retinalendothelial cells: the role of mitochondrial reactive oxygenspecies. Mol Cell Biochem. 2010;343(1-2):27-35. doi: 10.1007/s11010-010-0495-5.

  22. Montesanto A, Crocco P, Dato S, Geracitano S, Frangipane F,Colao R, et al. Uncoupling protein 4 (UCP4) gene variability inneurodegenerative disorders: further evidence of association inFrontotemporal dementia. Aging (Albany NY). 2018;10(11):3283-3293. doi: 10.18632/aging.101632.

  23. Dossett LA, Cao H, Mowery NT, Dortch MJ, Morris JM Jr, MayAK. Blood glucose variability is associated with mortality in thesurgical intensive care unit. Am Surg. 2008;74(8):679-685;discussion 685. doi: 10.1177/000313480807400802.

  24. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF,Hoekstra JB, Devries JH. Glucose variability is associated withintensive care unit mortality. Crit Care Med. 2010;38(3):838-842.doi: 10.1097/CCM.0b013e3181cc4be9.

  25. Meynaar IA, Eslami S, Abu-Hanna A, van der Voort P, de LangeDW, de Keizer N. Blood glucose amplitude variability as predictorfor mortality in surgical and medical intensive care unit patients:a multicenter cohort study. J Crit Care. 2012;27(2):119-124. doi:10.1016/j.jcrc.2011.11.004.

  26. Eslami S, Taherzadeh Z, Schultz MJ, Abu-Hanna A. Glucosevariability measures and their effect on mortality: a systematicreview. Intensive Care Med. 2011;37(4):583-593. doi: 10.1007/s00134-010-2129-5.

  27. Kovatchev B, Cobelli C. Glucose variability: timing, risk analysis,and relationship to hypoglycemia in diabetes. Diabetes Care.2016;39(4):502-510. doi: 10.2337/dc15-2035.

  28. Lanspa MJ, Krinsley JS, Hersh AM, Wilson EL, Holmen JR,Orme JF, et al. Percentage of time in range 70 to 139 mg/dLis associated with reduced mortality among critically ill patientsreceiving iv insulin infusion. Chest. 2019;156(5):878-886. doi:10.1016/j.chest.2019.05.016.

  29. Jeschke MG. Clinical review: Glucose control in severely burnedpatients - current best practice. Crit Care. 2013;17(4):232.

  30. Jeschke MG, Chinkes DL, Finnerty CC, Kulp G, Suman OE, NorburyWB, et al. Pathophysiologic response to severe burn injury. AnnSurg. 2008;248(3):387-401. doi: 10.1097/SLA.0b013e3181856241.

  31. Gore DC, Chinkes D, Heggers J, Herndon DN, Wolf SE, DesaiM. Association of hyperglycemia with increased mortalityafter severe burn injury. J Trauma. 2001;51(3):540-544. doi:10.1097/00005373-200109000-00021.

  32. Gore DC, Chinkes DL, Hart DW, Wolf SE, Herndon DN, SanfordAP. Hyperglycemia exacerbates muscle protein catabolism inburn-injured patients. Crit Care Med. 2002;30(11):2438-2442.doi: 10.1097/00003246-200211000-00006.

  33. Wilmore DW, Long JM, Mason AD Jr, Skreen RW, Pruitt BAJr. Catecholamines: mediator of the hypermetabolic responseto thermal injury. Ann Surg. 1974;180(4):653-669. doi:10.1097/00000658-197410000-00031.




2020     |     www.medigraphic.com